Addex Therapeutics Ltd., of Geneva, appointed Mark F. Bear, Peter R. Bernstein and Bernard Bettler to its scientific advisory board.
Akcea Therapeutics Inc., of Boston, appointed Michael D. Price executive vice president and chief financial officer.
Ardelyx Inc., of Fremont, Calif., appointed Susan Rodriguez chief commercial officer.
Asklepios Biopharmaceutical Inc. (Askbio), of Research Triangle Park, N.C., appointed Tim Trost chief financial officer.
Cellectis SA, of Paris, appointed Leopold Bertea senior vice president of technical operations - Europe.
Evox Therapeutics Ltd., of Oxford, U.K., appointed Sonya Montgomery chief medical officer.
Matrisys Bioscience Inc., of San Diego, appointed James Mackay to its board.
Merck & Co. Inc., of Kenilworth, N. J., appointed Matthew Walsh chief financial officer and Rachel Stahler chief information officer for Organon & Co.
Oligomerix Inc., of New York, appointed William Erhardt chief medical officer and Robert Foerster chief financial officer.
Science 37 Inc., of Los Angeles, appointed Mike Zaranek chief financial officer.
Selexis SA, of Geneva, appointed Myriam Adam vice president, operations and intellectual property; Séverine Fagète vice president, cell line development services; and Valérie Le Fourn vice president, research.
Tonix Pharmaceuticals Holding Corp., of New York, appointed Herbert Harris executive vice president, translational medicine.